Clínic Barcelona. Hospital Universitari

Hemostasis Clinical hemostasis and specialized laboratories

We perform direct patient assessment and medical interconsultations, as well as more complex diagnostic testing and support for the clinical activity.
Specialized areas:

• Primary hemostasis, platelet dysfunction and antiplatelet therapy: focused on diagnosing patients with platelet pathology, and laboratory evaluation of the response to antiplatelet therapy.
We provide support for direct clinical care of patients attended in the bleeding diathesis area, and perform functional studies, flow cytometry, proteomic determinations, and other complex tests.
More than 1000 tests per year are carried out, a part of them requiring highly complex techniques.
• Hemophilia and bleeding diathesis: directed toward the care and follow-up of patients with bleeding problems.
We provide a 24-hour continuum of care for patients with bleeding disorders. Together with the thrombosis area, we attend to more than 1500 patients in the Day Hospital, around 6500 intrahospital requests, and approximately 1800 outpatient requests.

To attain a precise diagnosis of bleeding disorders, specialized laboratories for this purpose are available in the same area as the Hemostasis Section. The complex tests performed range from functional diagnostics to genetic studies. The Primary Hemostasis Area also carries out plasma studies and platelet function studies.
More than 2000 complex tests are performed per year. We also provide urgent testing for Hemostasis, lending support to the Core Laboratory in situations that require an immediate diagnosis by special tests.

• Thrombophilia and prethrombotic states: covers the diagnosis and treatment of patients with thrombotic diseases or a risk of acquiring these diseases.
We offer urgent testing for Hemostasis, performed in the Core Laboratory. The special Hemostasis laboratories provide support in situations that require an immediate diagnosis using special tests. Direct attention for patients with conditions in this field is carried out within the Thrombotic Disease Area.
Precise diagnosis of thrombotic disorders is achieved by laboratories specialized in evaluating the risk of thrombosis, where complex tests are performed. These range from functional diagnostics to genetic studies, as well as plasma studies.
Every year, more than 2000 complex tests are performed.

• Thrombotic disease and antithrombotic treatment: focused on the care and follow-up of patients with thrombotic problems.

We provide 24-hour service for patients with thrombotic disorders and those under treatment with antithrombotic agents. One key activity is follow-up and monitoring of oral anticoagulant therapy (OAT). We attend 350 patients daily for this purpose, with a yearly increase of 12% to 15%. In OAT monitoring, we establish 90 000 doses per year.

An automated system for telephone contact is available to counsel patients on appropriate dosing and provide other complementary information. We also attend to in-hospital and outpatient consultations, interactions with other Departments, institutes, or centers that refer patients, and serve the Outpatient Clinic, hospital interconsultations, emergency requests, and the Day Hospital.
Molecular biology in Hemotherapy-Hemostasis: diagnostics and genetic counseling for patients with genetic abnormalities related to the Department’s areas of activity.

More than 1000 determinations of various parameters are performed per year for approximately 500 patients.

• Red blood cell disorders: specialized diagnosis of rare red cell diseases and uncommon anemias, including the diagnosis of structural and enzymatic red blood cell abnormalities.
Our activity is mainly focused on evaluation of erythrocyte enzymes, with analysis of more than 30 different parameters. Nearly 2500 determinations are performed yearly.

We are a national and European reference center providing diagnostic services to multiple hospitals, and are specialized in the diagnosis of rare anemias. Hospital Clínic–IDIBAPS coordinates the European Network for Rare and Congenital Anæmias (ENERCA) project, subsidized by the European Community. The objective of this project is to share the advances and experience in this field and to help physicians obtain detailed information on these rare conditions. The Network’s activity is centralized in the Red Blood Cell Disorder Laboratory.

Return to Hemostasis


Juan Carlos Reverter (Head of Department)

Juan Carlos Reverter

Head of Department

Department of Hemotherapy and Hemostasis

Head of Section


Biomedical Diagnostic Center (CDB)

Villarroel, 170 · 08036 Barcelona
Tel: +34 93 227 54 64 · Fax: +34 93 227 98 75 · ·